S&P 500 6,976.44 ▲ 37.41 (+0.54%)
DOW 49,407.66 ▲ 515.19 (+1.05%)
NASDAQ 23,592.11 ▲ 130.29 (+0.56%)
US Markets Closed

ACXP

Acurx Pharmaceuticals, Inc.

Price Chart
Latest Quote

$2.38

Current Price
Previous Close $2.37
Open $2.41
Day High $2.49
Day Low $2.37
Volume 53,395
Fetched: 2026-02-03T01:48:48
Stock Information
Shares Outstanding 2.35M
Cash Equivalents $5.91M
Net Income $-9.17M
Sector Healthcare
Industry Biotechnology
Market Cap $5.59M
EPS (TTM) $-8.18
Exchange NCM
🌐 Visit Website
📊 Custom Metrics & Score
Score: 12/42
Debt to Equity 5.27
Debt to Earnings -0.23
Current Ratio 1.19
Quick Ratio 1.16
Return on Equity -2292.74%
Avg FCF Growth 26.78%
FCF Yield -185.80%
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
Date Close Volume
2026-02-02 $2.38 53,395
2026-01-30 $2.37 58,700
2026-01-29 $2.49 62,400
2026-01-28 $2.59 36,100
2026-01-27 $2.68 26,200
2026-01-26 $2.74 23,700
2026-01-23 $2.75 61,200
2026-01-22 $2.78 55,900
2026-01-21 $2.54 37,900
2026-01-20 $2.55 50,300
2026-01-16 $2.65 17,200
2026-01-15 $2.69 57,000
2026-01-14 $2.74 35,700
2026-01-13 $2.73 52,900
2026-01-12 $2.78 35,200
2026-01-09 $2.93 25,200
2026-01-08 $2.92 60,500
2026-01-07 $2.91 172,000
2026-01-06 $2.92 40,400
2026-01-05 $2.86 47,900
About Acurx Pharmaceuticals, Inc.

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia; and CCP, multiple product candidates for gram-positive infections. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.

📰 Latest News
Loss-Making Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Expected To Breakeven In The Medium-Term
Simply Wall St. â€ĸ 2026-01-21T12:28:16Z
Article thumbnail
Has Acurx Pharmaceuticals (ACXP) Outpaced Other Medical Stocks This Year?
Zacks â€ĸ 2026-01-06T14:40:03Z
Article thumbnail
Are Medical Stocks Lagging Acurx Pharmaceuticals (ACXP) This Year?
Zacks â€ĸ 2025-06-18T13:40:03Z
Article thumbnail
Sector Update: Health Care Stocks Retreat Late Afternoon
MT Newswires â€ĸ 2025-06-17T19:53:56Z
Acurx Pharmaceuticals (ACXP) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Zacks â€ĸ 2025-04-08T13:55:04Z
Article thumbnail
Acurx Pharmaceuticals, Inc. (ACXP): Insider Were Buying In Q1 2025
Insider Monkey â€ĸ 2025-04-02T19:30:55Z
Article thumbnail
Acurx Pharmaceuticals Inc (ACXP) Q4 2024 Earnings Call Highlights: Advancing Antibiotic Trials ...
GuruFocus.com â€ĸ 2025-03-24T01:00:20Z
Acurx Pharmaceuticals (ACXP) Upgraded to Buy: Here's What You Should Know
Zacks â€ĸ 2025-03-21T16:00:08Z
Article thumbnail
Income Statement (Annual)
Revenue
Metric 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total Revenue $0 $0 $0 $0
Operating Revenue $0 $0 $0 $0
Expenses
Metric 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total Expenses $14,103,103 $14,577,768 $12,092,776 $12,814,200
Operating Expense $14,103,103 $14,577,768 $12,092,776 $12,814,200
General And Administrative Expense $8,699,267 $8,534,171 $7,338,505 $10,784,023
Other Income Expense - - - $66,503
Income & Earnings
Metric 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Net Income From Continuing Operation Net Minority Interest $-14,103,103 $-14,577,768 $-12,092,776 $-12,747,697
Normalized Income $-14,103,103 $-14,577,768 $-12,092,776 $-12,814,200
Net Income From Continuing And Discontinued Operation $-14,103,103 $-14,577,768 $-12,092,776 $-12,747,697
Net Income Common Stockholders $-14,103,103 $-14,577,768 $-12,092,776 $-12,747,697
Net Income $-14,103,103 $-14,577,768 $-12,092,776 $-12,747,697
Net Income Including Noncontrolling Interests $-14,103,103 $-14,577,768 $-12,092,776 $-12,747,697
Net Income Continuous Operations $-14,103,103 $-14,577,768 $-12,092,776 $-12,747,697
Pretax Income $-14,103,103 $-14,577,768 $-12,092,776 $-12,747,697
Operating Income $-14,103,103 $-14,577,768 $-12,092,776 $-12,814,200
Special Income Charges - - $0 $66,503
Per Share Metrics
Metric 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Diluted EPS $-17.40 $-23.00 $-22.40 $-29.80
Basic EPS $-17.40 $-23.00 $-22.40 $-29.80
Other
Metric 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Tax Effect Of Unusual Items $0 $0 $0 $0
Tax Rate For Calcs $0 $0 $0 $0
Normalized EBITDA (Bullshit earnings) $-14,103,103 $-14,577,768 $-12,092,776 $-12,880,703
EBITDA (Bullshit earnings) $-14,103,103 $-14,577,768 $-12,092,776 $-12,814,200
EBIT $-14,103,103 $-14,577,768 $-12,092,776 $-12,814,200
Diluted Average Shares $808,168 $633,578 $540,820 $426,793
Basic Average Shares $808,168 $633,578 $540,820 $426,793
Diluted NI Availto Com Stockholders $-14,103,103 $-14,577,768 $-12,092,776 $-12,747,697
Research And Development $5,403,836 $6,043,597 $4,754,271 $2,030,177
Selling General And Administration $8,699,267 $8,534,171 $7,338,505 $10,784,023
Other Gand A $8,699,267 $8,534,171 $7,338,505 $10,784,023
Total Unusual Items - - $0 $66,503
Total Unusual Items Excluding Goodwill - - $0 $66,503
Other Special Charges - - - $-66,503
Fetched: 2026-02-02
Balance Sheet (Annual)
Assets
Metric 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Net Tangible Assets $615,121 $4,666,685 $7,315,021 $12,410,241
Total Assets $3,857,963 $7,709,123 $9,376,706 $13,254,150
Total Non Current Assets $0 $0 $0 $0
Current Assets $3,857,963 $7,709,123 $9,376,706 $13,254,150
Prepaid Assets $100,123 $105,776 $264,955 $295,304
Receivables $51,127 $129,159 $0 -
Other Receivables $51,127 $129,159 - -
Cash Cash Equivalents And Short Term Investments $3,706,713 $7,474,188 $9,111,751 $12,958,846
Cash And Cash Equivalents $3,706,713 $7,474,188 $9,111,751 $12,958,846
Cash Financial $3,706,713 $7,474,188 $9,111,751 $12,958,846
Liabilities
Metric 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total Liabilities Net Minority Interest $3,242,842 $3,042,438 $2,061,685 $843,909
Total Non Current Liabilities Net Minority Interest $0 $0 $0 $0
Current Liabilities $3,242,842 $3,042,438 $2,061,685 $843,909
Payables And Accrued Expenses $2,705,212 $2,326,131 $1,518,790 $335,566
Payables $4,787 $3,809 $29,539 $63,374
Other Payable $4,787 $3,809 $29,539 $63,374
Equity
Metric 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Common Stock Equity $615,121 $4,666,685 $7,315,021 $12,410,241
Total Equity Gross Minority Interest $615,121 $4,666,685 $7,315,021 $12,410,241
Stockholders Equity $615,121 $4,666,685 $7,315,021 $12,410,241
Retained Earnings $-67,321,956 $-53,218,853 $-38,641,085 $-26,548,309
Gains Losses Not Affecting Retained Earnings - - $-38,641,085 $-26,548,309
Other Equity Adjustments - - $-38,641,085 $-26,548,309
Other
Metric 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Ordinary Shares Number $851,534 $723,411 $581,380 $510,789
Share Issued $851,534 $723,411 $581,380 $510,789
Tangible Book Value $615,121 $4,666,685 $7,315,021 $12,410,241
Invested Capital $615,121 $4,666,685 $7,315,021 $12,410,241
Working Capital $615,121 $4,666,685 $7,315,021 $12,410,241
Total Capitalization $615,121 $4,666,685 $7,315,021 $12,410,241
Additional Paid In Capital $67,920,046 $57,871,070 $45,944,478 $38,948,334
Capital Stock $17,031 $14,468 $11,628 $10,216
Common Stock $17,031 $14,468 $11,628 $10,216
Pensionand Other Post Retirement Benefit Plans Current $537,630 $716,307 $542,895 $508,343
Current Accrued Expenses $2,700,425 $2,322,322 $1,489,251 $272,192
Treasury Shares Number - $0 - -
Total Partnership Capital - $-53,218,853 $-38,641,085 -
Fetched: 2026-02-02
Cash Flow Statement (Annual)
Free Cash Flow
Metric 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Free Cash Flow $-10,383,431 $-9,800,885 $-7,542,290 $-5,013,697
Operating Activities
Metric 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Operating Cash Flow $-10,383,431 $-9,800,885 $-7,542,290 $-5,013,697
Cash Flow From Continuing Operating Activities $-10,383,431 $-9,800,885 $-7,542,290 $-5,013,697
Operating Gains Losses - - - $850,262
Financing Activities
Metric 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Issuance Of Capital Stock $6,405,757 $5,944,250 $3,695,182 $14,797,132
Financing Cash Flow $6,615,956 $8,163,322 $3,695,195 $14,797,132
Cash Flow From Continuing Financing Activities $6,615,956 $8,163,322 $3,695,195 $14,797,132
Net Common Stock Issuance $6,405,757 $5,944,250 $3,695,182 $14,797,132
Common Stock Issuance $6,405,757 $5,944,250 $3,695,182 $14,797,132
Other
Metric 2024-12-31 2023-12-31 2022-12-31 2021-12-31
End Cash Position $3,706,713 $7,474,188 $9,111,751 $12,958,846
Beginning Cash Position $7,474,188 $9,111,751 $12,958,846 $3,175,411
Changes In Cash $-3,767,475 $-1,637,563 $-3,847,095 $9,783,435
Proceeds From Stock Option Exercised $210,199 $2,219,072 $13 $0
Change In Working Capital $284,089 $1,010,773 $1,248,125 $141,283
Change In Payables And Accrued Expense $200,404 $980,753 $1,217,776 $387,978
Change In Prepaid Assets $5,653 $159,179 $30,349 $-246,695
Change In Receivables $78,032 $-129,159 $0 -
Stock Based Compensation $3,435,583 $3,766,110 $3,302,361 $6,742,455
Net Income From Continuing Operations $-14,103,103 $-14,577,768 $-12,092,776 $-12,747,697
Other Non Cash Items - $559,583 $430,680 $1,587,741
Pension And Employee Benefit Expense - - $0 $916,765
Issuance Of Debt - - - $0
Net Issuance Payments Of Debt - - - $0
Net Long Term Debt Issuance - - - $0
Long Term Debt Issuance - - - $0
Fetched: 2026-02-02